Biologic Fails in Kidney Disorder MedPage Today The addition of rituximab (Rituxan) to a standard immunosuppressive regimen failed to increase the overall response rate among patients with lupus nephritis. Note that adverse event rates overall were similar in the rituximab and placebo groups, ... |
